Pancreatic Cancer Clinical Trial
Official title:
Extended Versus Standard Resection in Two Cohorts of Patients With Adenocarcinoma of the Pancreas: Minimal Metastatic Disease or Venous Infiltration - a Randomized Trial
PaMeViTUM is a mono-centric prospective randomized controlled trial that compares different operating procedures in patients with pancreatic cancer and minimal metastatic disease or venous infiltration.
PaMeViTUM is a mono-centric prospective randomized controlled trial comparing different
operating procedures in patients with pancreatic cancer and minimal metastatic disease or
venous infiltration. Patients will be randomized intraoperatively after fulfilling all
inclusion criteria (in particular: suspicion of cancer of the pancreas and an intraoperative
histologically proven diagnosis of pancreatic adenocarcinoma; intraoperative assessment of
tumor as potentially locally respectable). If no metastases and no infiltration of the
portal vein are detected during the operation, the standard resection will be performed (for
tumors of the pancreatic head: (pylorus-preserving) pancreaticoduodenectomy; for tumors of
the pancreatic body/tail: distal (left) pancreatic resections; for tumors of the head and
body/tail: total pancreatectomy). In the case of tumor infiltration of the pyloric region or
the distal stomach, a classical pancreaticoduodenectomy will be performed.
If the patient has pancreatic cancer with minimal metastatic disease (COHORT 1) and fulfills
all inclusion criteria, she/he will be randomized into one of the following arms:
- Arm 1 (intervention): resection of the primary tumor, followed by resection of the
liver metastasis/metastases
- Arm 2 (control): exploration and/or gastroenterostomy and/or
hepaticojejunostomy/choledochojejunostomy
If there are no liver metastases, following mobilization (and potentially also the
dissection of the pancreas at the pancreatic head), the extension of the tumor towards the
superior mesenteric/splenic/portal vein is examined. If there is venous infiltration (COHORT
2) and the patient fulfills the inclusion criteria, she/he will be randomized into one of
the following arms:
- Arm 1 (intervention): resection of the primary tumor with resection of the portal vein
(and/or superior mesenteric vein/splenic vein (SMV/SV)
- Arm 2 (control): resection of the primary tumor with dissection of the portal vein
(and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to
these veins; no venous resection The aim of this study is to demonstrate that an
extension of the resectability criteria in patients with pancreatic cancer and 1)
minimal metastatic disease OR 2) venous infiltration improves overall survival. A
secondary aim of the study is to prove that resection in these patient cohorts improves
quality of life.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|